SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001600620-24-000001
Filing Date
2024-01-05
Accepted
2024-01-05 06:02:28
Documents
13
Period of Report
2024-01-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K auph-20240105.htm   iXBRL 8-K 30261
2 EX-99.1 auph4qpreannounceprjanuary.htm EX-99.1 21910
  Complete submission text file 0001600620-24-000001.txt   185108

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT auph-20240105.xsd EX-101.SCH 1932
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT auph-20240105_lab.xml EX-101.LAB 23834
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT auph-20240105_pre.xml EX-101.PRE 12532
7 EXTRACTED XBRL INSTANCE DOCUMENT auph-20240105_htm.xml XML 2720
Mailing Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6
Business Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6 250-744-2487
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

IRS No.: 981231763 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36421 | Film No.: 24514362
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)